LauraFNewellMD
Hematology • Portland, ORInstructor, Medicine, Oregon Health and Science University School of Medicine
Dr. Newell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
# L586
Portland, OR 97239Phone+1 503-494-6346Fax+1 503-346-8015
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2007 - 2010
University of California Davis HealthResidency, Internal Medicine, 2004 - 2007
University of California, Davis, School of MedicineClass of 2004
Certifications & Licensure
CA State Medical License 2005 - Present
OR State Medical License 2011 - 2025
WA State Medical License 2007 - 2012- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Publications & Presentations
PubMed
- 169 citationsIdentification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid LeukemiaAlyssa Carey, David K. Edwards, Christopher A. Eide, Laura F. Newell, Elie Traer
Cell Reports. 2017-03-28 - 205 citationsAdvances in acute myeloid leukemiaLaura F. Newell, Rachel J. Cook
BMJ. 2021-10-06 - 585 citationsCPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute My...Jeffrey E. Lancet, Geoffrey L. Uy, Jorge E. Cortes, Laura F. Newell, Tara L. Lin
Journal of Clinical Oncology. 2018-07-19
Abstracts/Posters
- Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...Laura F. Newell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...Laura F. Newell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...Laura F. Newell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
OHSU Second in Country to Perform Regenerative Brain Cell Therapy ProcedureNovember 3rd, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
